Navigation Links
InterMune to Webcast 2011 Analyst Day Presentations
Date:5/19/2011

BRISBANE, Calif., May 19, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) will conduct a live webcast of its 2011 Analyst Day presentations on Thursday, May 26, 2011, from 8:30 a.m. – 11:30 a.m. EDT in New York.  Presentations by InterMune's executive management team will provide an overview of the company's vision, strategy and a comprehensive update of InterMune's commercial and scientific plans.  The company also will provide details on its preparations to launch Esbriet® (pirfenidone) for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis (IPF) in Europe and on ASCEND, a new Phase 3 study of pirfenidone, including study design, scientific rationale and guidance on important study and NDA resubmission milestones.

To access the webcast of the Analyst Day presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
2. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
3. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 28
5. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
6. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
7. InterMune to Release Third Quarter Financial Results on October 28
8. InterMune Sells Danoprevir Rights to Roche for $175 Million
9. InterMune to Present at 2010 Citi Health Care Conference
10. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
11. InterMune to Release First Quarter Financial Results on April 29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... , ... February 04, 2016 , ... ... development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Sangamo BioSciences, ... genome editing, announced today that Edward Lanphier , ... update on the progress of Sangamo,s ZFP Therapeutic ® ... business strategy at 2:40 pm ET on Thursday, February ... Annual Global Healthcare Conference. The conference is being held ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
Breaking Biology News(10 mins):